Roche’s Tecentriq Receives EU’s CHMP Recommendation for its Approval as 1L Therapy for Extensive-Stage Small Cell Lung Cancer

 Roche’s Tecentriq Receives EU’s CHMP Recommendation for its Approval as 1L Therapy for Extensive-Stage Small Cell Lung Cancer

Roche’s Tecentriq Receives EU’s CHMP Recommendation for its Approval as 1L Therapy for Extensive-Stage Small Cell Lung Cancer

Shots:

  • The CHMP’s positive recommendation is based on P-III IMpower133 study results assessing Tecentriq + CT vs CT (carboplatin and etoposide) in 403 patients in a ratio (1:1) with ES-SCLC
  • The P-III IMpower133 study results: OS (12.3 vs 10.3 mos.); PFS (5.2 vs 4.3 mos.). Tecentriq based combination therapy is expecting its European Commission’s approval following the CHMP’s positive recommendation
  • Tecentriq is a mAb targeting PD-L1, blocking its interaction with PD-1 and B7.1 receptor, thus enabling the interaction of T-cells and is an approved therapy for multiple cancer indications in the US & EU

Click here to­ read full press release/ article | Ref: Roche | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post